SABCS 2022 | Genomic and transcriptomic landscape of HER2-low breast cancer

Rani Bansal, MD, Duke Cancer Center, Durham, NC, discusses an investigation into the genomic and transcriptomic landscape of HER2-low breast cancer. HER2-Low is defined as tumors with HER2 IHC score of 1+ as well as those with 2+ with paired negative in-situ hybridization assay. The Caris Life Sciences database was used to identify HER2-low breast tumors by IHC and CISH and evaluated for mutations detected by DNA next-generation sequencing. A total of 19789 breast tumors were included in this studied to identify genomic differences between HER2-low and HER2-negative breast cancers. Significant differences were not observed in terms of mutational burden and markers of immune response, however there was a difference in the mutation rate of PIK3CA between HER2-low and HR-negative/HER2-negative breast cancers. Overall, these findings indicate HER2-low is not a separate entity. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.